Pharmaceutical Technology

JULY 14, 2025

Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster. How will RFK Jr’s American dream for vaccines play out? Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Vaccines

Pharmaceutical Technology

JULY 2, 2025

With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. How will RFK Jr’s American dream for vaccines play out? As of December 2024, the company reported cash reserves of $85.2m.

Packaging

BioPharma Dive

JUNE 27, 2025

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from News roundup Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules Biocryst is offloading part of its business to an Italian drugmaker for $250 million upfront.

Vaccines

Pharmaceutical Technology

JULY 17, 2025

Find out more After its strategic review, the company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability. This approach should maintain access to a $600m revolving credit facility while managing liabilities proactively, including repayment of convertible notes due in 2027.

Insurance Coverage and Processing

STAT

DECEMBER 7, 2023

One expires next year and the other in 2027, well beyond the original patent expiration date. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.

Drug Pricing

STAT

SEPTEMBER 23, 2024

Now, all eyes are on which Part D drugs will be chosen for the next round of 15 drugs. 1, and the negotiated prices of those drugs take effect in 2027.  Medicare will announce that list by Feb.

Specialty Pharmacies

STAT

JULY 24, 2023

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

Packaging

The Guardian - Pharmaceutical Industry

SEPTEMBER 21, 2023

The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF).

Drug Pricing

STAT

JULY 25, 2023

The House Ways & Means Committee proposed a package that includes a new provision to ensure Medicare patients pay for medicines they pick up at pharmacies based on discounted prices insurers negotiate with drugmakers, instead of higher list prices, starting in 2027 , STAT reports.

Packaging

Putting Patients First Blog

SEPTEMBER 3, 2024

Overall, while the NHC appreciates CMS’ intent to streamline the data submission process and make it more accessible, we encourage ongoing dialogue and adjustments to ensure that the process remains patient-centered, efficient, and capable of capturing the full spectrum of information necessary to inform meaningful drug price negotiations.

Drug Pricing

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). Valuing life differently based on disability status, age, or other special populations is inappropriate.

Drug Pricing

Putting Patients First Blog

APRIL 27, 2023

NHC Medicare Drug Price Negotiation Program Comments April 27, 2023 By: Allen Pinn, Coordinator, Policy April 14, the National Health Council (NHC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act.

Drug Pricing

Big Molecule Watch

NOVEMBER 6, 2023

The licensure and marketing of WEZLANA could affect negotiations with CMS regarding Medicare pricing for STELARA under the Inflation Reduction Act’s Drug Price Negotiation Program. FDA’s approval of WEZLANA has also been raised as a pertinent fact in one of the pending challenges to the Drug Price Negotiation Program.

Drug Pricing

Big Molecule Watch

MAY 9, 2024

Quraishi) granted summary judgment for the Government in two cases, brought by BMS and Janssen, challenging the IRA’s Drug Price Negotiation Program. Briefing on dispositive motions has completed in the remaining district court challenges to the Drug Price Negotiation Program. Lead Case No.

Drug Pricing

pharmaphorum

JUNE 8, 2021

.” Biogen has committed not to raise the price of Aduhelm for four years and said it has agreed access deals with some payers – including the Veterans Health Administration, CVS Health and the National Association of Free and Charitable Clinics (NAFC) – while negotiations are ongoing with Cigna and other groups. billion in 2027.

Labelling

FDA Law Blog: Biosimilars

MARCH 5, 2024

By Faraz Siddiqui — Last Friday, the Delaware District Court rejected AstraZeneca’s lawsuit against the Medicare Drug Price Negotiation Program enacted under the Inflation Reduction Act (IRA) and CMS’s guidance implementing it.

Dosage

Putting Patients First Blog

APRIL 14, 2023

The NHC requests insight on what opportunities CMS plans to put forward for stakeholders to provide formal input into adjusting future program guidance and whether there will be a comment opportunity to inform negotiation for IPAY 2027 and beyond. The negotiation program is a new policy that is being implemented in a non-traditional manner.

Drug Pricing

Putting Patients First Blog

SEPTEMBER 20, 2024

NHC Provides Input on Patient Engagement in Medicare Drug Price Negotiations September 20, 2024 By: Allen Pinn, Coordinator, Policy August 16 marked two years since the Inflation Reduction Act (IRA) was signed into law. Earlier this year CMS released draft guidance for Initial Payment Applicability Year (IPAY) 2027.

Drug Pricing

Safe Biologics

MAY 10, 2024

View ASBM’s educational fact sheet “Interchangeability: US vs EU” here. Biden’s SOTU: 500 Drugs To Be Subject to Medicare Drug Price Controls On March 7th, President Biden gave his State of the Union address to Congress, wherein he laid out upcoming policy priorities for a potential second term.

Biosimilars

BioPharma Dive

JULY 21, 2025

While adalimumab biosimilars have captured approximately one-third of the market today, experts predict they will reach 60% by the end of 2027. If payers evaluate ustekinumab biosimilars primarily on cost, it will be interesting to track what happens early next year, when a new maximum fair price is slated to take effect for Stelara.

Biosimilars

BioPharma Dive

JULY 21, 2025

It has about $1 billion in debt due in 2027 and intends to speak with lenders this week to determine whether any of the myriad recent developments might constitute a “material adverse event” that could trigger financial fallout, executives told Leerink’s Schwartz. You can unsubscribe at anytime. Registered in England and Wales.

Specialty Pharmacies

BioPharma Dive

JUNE 30, 2025

The COVID-19 vaccine pioneer said it will begin discussing an approval submission with the Food and Drug Adminstration, aiming to launch what would be the first messenger RNA-based influenza vaccine in the U.S. as early as the 2026-2027 flu season. You can unsubscribe at anytime. Registered in England and Wales. TechTarget, Inc.s

Vaccines